TNO155B
Total Payments
$41,907
Transactions
5
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $41,487 | 3 | 0 |
| 2019 | $420.00 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $41,907 | 5 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE IB, OPEN-LABEL, MULTI-CENTER STUDY TO CHARACTERIZE THE SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF TNO155 IN COMBINATION WITH SPARTALIZUMAB OR RIBOCICLIB IN SELECTED MALIGNANCIES | Novartis Pharmaceuticals Corporation | $41,907 | 0 |
Top Doctors Receiving Payments for TNO155B
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Nashville, TN | $41,907 | 5 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $41,907
- Total Doctors 0
- Transactions 5
About TNO155B
TNO155B is a drug associated with $41,907 in payments to 0 healthcare providers, recorded across 5 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2019 to 2020. In 2020, $41,487 was paid across 3 transactions to 0 doctors.
The most common payment nature for TNO155B is "Unspecified" ($41,907, 100.0% of total).
TNO155B is associated with 1 research study, including "A PHASE IB, OPEN-LABEL, MULTI-CENTER STUDY TO CHARACTERIZE THE SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF TNO155 IN COMBINATION WITH SPARTALIZUMAB OR RIBOCICLIB IN SELECTED MALIGNANCIES" ($41,907).